[英文研究]在治疗慢性乙型肝炎临床实践,坚持核苷（酸）类

StephenW

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01494.x/abstract>
在治疗慢性乙型肝炎
临床实践,坚持核苷（酸）类似物和病毒突破的
相关
Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical
practice and correlation with virological breakthroughs

W. Chotiyaputta, C. Hongthanakorn, K. Oberhelman, R. J. Fontana, T. Licari,
A. S. F. Lok

Article first published online: 14 JUL 2011

DOI: 10.1111/j.1365-2893.2011.01494.x

© 2011 Blackwell Publishing Ltd
Issue

Journal of Viral Hepatitis
Early View (Online Version of Record published before inclusion in an
issue)

Summary.  Medication adherence is important for the success of
nucleos(t)ide analogue (NUC) treatment for chronic hepatitis B. The aims of
this study were to determine adherence to NUCs and factors associated with
NUC adherence and to correlate NUC adherence with the occurrence of
virological breakthroughs in patients with chronic hepatitis B. Consecutive
patients with chronic hepatitis B receiving NUC were asked to complete a
survey every 3 months. Adherence was also assessed by healthcare providers
in the clinic. Adherence rate was defined as the per cent of days the
patients took their hepatitis B virus medications during the last 30 days.
A total of 111 patients were studied. The mean age was 47.7 years, 73.9%
were men, 57.7% were Asian, 42.3% had postgraduate education and 80% had
private insurance. Sixty-nine (74.1%) patients reported 100% adherence in
the survey, while 78 (83.9%) reported 100% adherence to their healthcare
providers. Patients with 100% adherence based on the survey were older (P =
0.02), more likely to be men (P = 0.006), and had higher annual household
income (P = 0.04) than those with <100% adherence. In the 80 patients who
completed three surveys, viral breakthrough was observed in 1/46 (2.2%)
with 100% adherence on all three surveys, 1/18 (5.6%) with <100% adherence
on one survey and 3/16 (18.8%) with <100% adherence on ≥2 surveys, (P =
0.06). In conclusion, adherence to NUC therapy in our patients with chronic
hepatitis B was high but self-reporting of adherence to healthcare
providers may be inflated. Patients with chronic hepatitis B with better
adherence to NUC therapy had a trend towards a lower rate of viral
breakthroughs.

StephenW

谷歌翻译
不是100％准确，仅供参考使用。

摘要。
坚持服药是很重要的成功的核苷（酸）治疗慢性乙型肝炎的目的这项研究是坚持NUCs和相关因素，以确定NUC坚持和关联的发生与国统会坚持
在慢性乙型肝炎连续患者的病毒学突破
接收NUC与慢性肝炎的患者被要求完成
调查每3个月。坚持医疗服务提供者也进行了评估
在临床上。坚持率被定义为％的天
患者在过去30天里他们的B型肝炎病毒药物。
共有111名患者进行了研究。平均年龄为47.7岁，73.9％
为男性，57.7％是亚裔，42.3％的研究生教育和80​​％的
私人保险。 100％坚持在六十九名（74.1％）患者报告
调查结果显示，78例（83.9％）报告100％坚持他们的医疗保健
供应商。调查的基础上坚持100％的患者年龄较大（P =
0.02），更可能是男性（P = 0.006），并有较高的家庭每年
比<100％坚持的收入（P = 0.04）。在80例
完成了三次调查，病毒的突破是在1 / 46（2.2％）
100％，在所有三个调查，1 / 18（5.6％）<100％坚持遵守
一项调查显示，3 / 16 <100％≥2调查坚持的（18.8％），（P =
0.06）。总之，坚持NUC在我们的病人治疗慢性
B型肝炎高，但坚持医疗保健的自我报告
供应商可能会被夸大。慢性乙型肝炎患者更好
坚持NUC治疗迈向率较低的病毒趋势
突破。